Histamine Receptors: Gatekeepers of Immunological and Neurological Responses
Histamine, a biogenic amine, plays a crucial role in various physiological processes, including immune responses, gastric acid secretion, and neurotransmission. Central to the action of histamine are histamine receptors, which are distributed broadly across different tissues and cell types. This article delves into the nature, types, and functions of histamine receptors, highlighting their significance in immunological and neurological processes.
Understanding Histamine Receptors:
Histamine exerts its effects by binding to specific receptors on the surfaces of target cells. These receptors are part of the G protein-coupled receptor (GPCR) family, characterized by their seven transmembrane domains. To date, four types of histamine receptors have been identified: H1, H2, H3, and H4. Each receptor subtype has distinct signaling mechanisms and tissue distribution, contributing to the diverse actions of histamine.
H1 Histamine Receptors:
The H1 receptors are widely distributed in endothelial and smooth muscle cells, as well as in the central nervous system (CNS). Activation of H1 receptors mediates various allergic reactions, such as vasodilation, increased vascular permeability, and bronchoconstriction. In the CNS, these receptors are involved in regulating sleep-wake cycles, appetite, and cognitive functions.
H2 Histamine Receptors:
Found predominantly in the stomach lining, H2 receptors play a pivotal role in regulating gastric acid secretion. Their activation stimulates the production of gastric acid, facilitating digestion. H2 receptors are also present in the heart and vascular smooth muscle cells, where they contribute to cardiac rhythm regulation and vasodilation.
H3 Histamine Receptors:
H4 Histamine Receptors:
The H4 receptor is the latest addition to the histamine receptor family, predominantly expressed in bone marrow and white blood cells. These receptors are involved in mediating chemotaxis and cytokine production, playing a significant role in immune response regulation and inflammation. The H4 receptor's role in itch and pain perception is also being explored.
Clinical Implications and Therapeutic Targets:
Exploring Histamine Receptor Function with Assay Genie:
References
- Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R., and Haas, H.L., 1997. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacological Reviews, 49(3), pp.253-278.
- Panula, P., Chazot, P.L., Cowart, M., Gutzmer, R., Leurs, R., Liu, W.L.S., Stark, H., Thurmond, R.L., and Haas, H.L., 2015. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacological Reviews, 67(3), pp.601-655.
- Simons, F.E.R., 2004. Advances in H1-Antihistamines. New England Journal of Medicine, 351(21), pp.2203-2217.
- O'Mahony, L., Akdis, M., and Akdis, C.A., 2011. Regulation of the immune response and inflammation by histamine and histamine receptors. Journal of Allergy and Clinical Immunology, 128(6), pp.1153-1162.
- Parsons, M.E. and Ganellin, C.R., 2006. Histamine and its receptors. British Journal of Pharmacology, 147(S1), S127-S135.
- Haas, H.L., Sergeeva, O.A., and Selbach, O., 2008. Histamine in the nervous system. Physiological Reviews, 88(3), pp.1183-1241.
- Thurmond, R.L., Gelfand, E.W., and Dunford, P.J., 2008. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nature Reviews Drug Discovery, 7(1), pp.41-53.
- Nieto-Alamilla, G., Márquez-Gómez, R., García-Gálvez, A.M., Morales-Figueroa, G.E., and Arias-Montaño, J.A., 2016. The Histamine H3 Receptor: Structure, Pharmacology, and Function. Molecular Pharmacology, 90(5), pp.649-673.
Written by Tehreem Ali
Tehreem Ali completed her MS in Bioinformatics and conducted her research work at the IOMM lab at GCUF, Pakistan.
Recent Posts
-
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the …17th Dec 2025 -
Alemtuzumab Biosimilar: Advancing CD52-Targeted Therapy
Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed on …17th Dec 2025 -
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as F …17th Dec 2025